| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
33.60
|
|
2
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
|
J Clin Oncol
|
2006
|
25.12
|
|
3
|
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
J Clin Oncol
|
2010
|
14.41
|
|
4
|
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
|
J Clin Oncol
|
2013
|
12.57
|
|
5
|
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
|
N Engl J Med
|
2016
|
8.53
|
|
6
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
|
Arch Pathol Lab Med
|
2007
|
8.02
|
|
7
|
Use of archived specimens in evaluation of prognostic and predictive biomarkers.
|
J Natl Cancer Inst
|
2009
|
7.95
|
|
8
|
Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
|
J Clin Oncol
|
2008
|
6.31
|
|
9
|
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
|
N Engl J Med
|
2015
|
5.57
|
|
10
|
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2006
|
4.99
|
|
11
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version).
|
Arch Pathol Lab Med
|
2010
|
4.38
|
|
12
|
Development of the 21-gene assay and its application in clinical practice and clinical trials.
|
J Clin Oncol
|
2008
|
3.89
|
|
13
|
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
|
J Clin Oncol
|
2002
|
3.82
|
|
14
|
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
J Clin Oncol
|
2010
|
3.79
|
|
15
|
Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
|
J Clin Oncol
|
2007
|
3.51
|
|
16
|
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
|
J Clin Oncol
|
2010
|
3.19
|
|
17
|
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
|
Clin Cancer Res
|
2012
|
3.07
|
|
18
|
HER2 status and benefit from adjuvant trastuzumab in breast cancer.
|
N Engl J Med
|
2008
|
3.05
|
|
19
|
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
|
Arch Pathol Lab Med
|
2010
|
2.72
|
|
20
|
Gene expression profiling of breast cancer: a new tumor marker.
|
J Clin Oncol
|
2005
|
2.69
|
|
21
|
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
|
Lancet Oncol
|
2013
|
2.59
|
|
22
|
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
|
Arch Pathol Lab Med
|
2013
|
2.54
|
|
23
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
|
J Clin Oncol
|
2012
|
2.34
|
|
24
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
|
J Natl Cancer Inst
|
2013
|
2.28
|
|
25
|
HER2 testing in breast cancer: NCCN Task Force report and recommendations.
|
J Natl Compr Canc Netw
|
2006
|
2.15
|
|
26
|
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
|
J Clin Oncol
|
2013
|
2.12
|
|
27
|
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
Breast Cancer Res Treat
|
2011
|
2.08
|
|
28
|
A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes.
|
BMC Cancer
|
2010
|
1.91
|
|
29
|
Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer.
|
Clin Cancer Res
|
2002
|
1.82
|
|
30
|
Nanomaterials for theranostics: recent advances and future challenges.
|
Chem Rev
|
2014
|
1.75
|
|
31
|
Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
|
Breast
|
2009
|
1.62
|
|
32
|
Gene-expression-based prognostic assays for breast cancer.
|
Nat Rev Clin Oncol
|
2010
|
1.47
|
|
33
|
Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.
|
J Clin Oncol
|
2013
|
1.46
|
|
34
|
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).
|
Breast Cancer Res Treat
|
2013
|
1.34
|
|
35
|
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2011
|
1.32
|
|
36
|
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.
|
J Clin Oncol
|
2009
|
1.25
|
|
37
|
Lower-category benign breast disease and the risk of invasive breast cancer.
|
J Natl Cancer Inst
|
2004
|
1.19
|
|
38
|
Research issues affecting preoperative systemic therapy for operable breast cancer.
|
J Clin Oncol
|
2008
|
1.18
|
|
39
|
Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
|
Clin Cancer Res
|
2008
|
1.13
|
|
40
|
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
|
Cancer Discov
|
2013
|
1.12
|
|
41
|
Expression analysis of mRNA in formalin-fixed, paraffin-embedded archival tissues by mRNA in situ hybridization.
|
Methods
|
2006
|
1.02
|
|
42
|
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
|
Clin Cancer Res
|
2011
|
0.98
|
|
43
|
Effects of tamoxifen on benign breast disease in women at high risk for breast cancer.
|
J Natl Cancer Inst
|
2003
|
0.98
|
|
44
|
Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer.
|
J Clin Oncol
|
2010
|
0.96
|
|
45
|
New generation of molecular prognostic and predictive tests for breast cancer.
|
Semin Oncol
|
2007
|
0.89
|
|
46
|
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
|
J Natl Cancer Inst
|
2013
|
0.89
|
|
47
|
An ideal prognostic test for estrogen receptor-positive breast cancer?
|
J Clin Oncol
|
2008
|
0.86
|
|
48
|
Predictive value of microsatellite instability-high remains controversial.
|
J Clin Oncol
|
2007
|
0.84
|
|
49
|
NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer.
|
Clin Breast Cancer
|
2006
|
0.83
|
|
50
|
Anthracyclines in the treatment of HER2-negative breast cancer.
|
J Natl Cancer Inst
|
2007
|
0.81
|
|
51
|
Genomics of adjuvant therapy for breast cancer.
|
Cancer J
|
2011
|
0.81
|
|
52
|
Colon cancer mutation: prognosis/prediction--response.
|
Clin Cancer Res
|
2013
|
0.80
|
|
53
|
Gene expression-based prognostic and predictive markers for breast cancer: a primer for practicing pathologists.
|
Arch Pathol Lab Med
|
2009
|
0.80
|
|
54
|
Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay.
|
Ann Hematol
|
2013
|
0.80
|
|
55
|
Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement.
|
Clin Cancer Res
|
2006
|
0.79
|
|
56
|
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
|
Breast Cancer Res Treat
|
2015
|
0.78
|
|
57
|
The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project.
|
Semin Oncol
|
2008
|
0.75
|
|
58
|
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.
|
Adv Anat Pathol
|
2017
|
0.75
|
|
59
|
Statistical considerations in assessing molecular markers for cancer prognosis and treatment efficacy.
|
Methods Mol Biol
|
2002
|
0.75
|
|
60
|
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
|
Clin Breast Cancer
|
2008
|
0.75
|
|
61
|
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
|
Adv Anat Pathol
|
2017
|
0.75
|